Skip to content
Review

Personalizing cardiovascular prevention in chronic kidney disease: an operational framework for risk-treatment mapping.

Aug 2026 · European journal of internal medicine · pp. 107117 · 0 citations · 38 references
Medicine

Abstract

Patients with chronic kidney disease (CKD) bear a disproportionate burden of cardiovascular (CV) morbidity and mortality, yet preventive strategies in clinical practice remain remarkably conservative and largely therapy-centered. The 2024 KDIGO guideline on CKD evaluation and management advocates the systematic use of validated prediction equations for kidney failure and CV outcomes, while contemporary CV prevention guidelines endorse multivariable risk tools that incorporate kidney measures. However, neither nephrology nor cardiology guidance has yet translated this risk-based paradigm into operational, bedside algorithms that link quantified risk to specific treatment combinations or incorporate frailty, life expectancy, and polypharmacy into decision-making. In this Review, we summarize contemporary risk prediction tools for kidney failure, CV events, and all-cause mortality in people with CKD, with a focus on models updated or externally validated after 2023. We examine how these tools reclassify risk compared with staging based on glomerular filtration rate (GFR) and albuminuria alone, and examine how they can underpin practical, absolute-risk-based strategies for layering disease-modifying therapies, including statins, renin-angiotensin-aldosterone system (RAAS) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RA), and finerenone. Finally, we address polypharmacy, deprescribing, and the challenges posed by extremes of age and CKD severity, arguing that personalized "risk-to-treatment" frameworks are now essential to navigate an increasingly complex therapeutic landscape.

View source

Similar papers

Review Open access Aug 2026

The Chronic Kidney Disease Care Model: Quantifying Management Strategies for Improving Patient Outcomes in the USA

The CKD Care Model provides a flexible, transparent tool for projecting the impact of eGFR decline on clinical outcomes and evaluating management strategies for CKD, and suggests that guideline-optimized treatment can improve patient outcomes at additional costs that appear favorable by conventional value-for-money sta...

Andrew H. Briggs, C. Kohli-Lynch, Adrian R. Levy et al. · 0 citations
Review Open access Sep 2026

Review of the Kidney Failure Risk Calculator (KFRE)

The kidney failure risk equation (KFRE) predicts the 2- and 5-year risk of kidney failure in stable patients with chronic kidney disease (CKD) stage 3-5 and can help improve prognostic communication and guide broader management decisions specifically, referral to nephrology, multidisciplinary CKD management and kidney...

Enock Arthur, Abinet M. Aklilu · 0 citations
Review Aug 2026

Reframing kidney outcomes in CKD trials: eGFR slopes, competing risks, and pragmatic trial design.

In both clinical research and study design, the definition of outcomes for chronic kidney disease (CKD) is changing. New molecules available for testing in humans, and the fact that kidney diseases are best treated earlier in their course, make the duration of studies requiring 'hard endpoints' longer than is feasible...

Carmine Zoccali, Adeera Levin · 0 citations
Review Sep 2026

Antihypertensive Pharmacotherapy in Chronic Kidney Disease: Integrating eGFR-Based Cutoffs, Mechanistic Insights, and Emerging Therapeutic Pathways.

A risk- and clinical-characteristic-guided approach that integrates kidney stage, degree of albuminuria, and overall cardiovascular risk is proposed to move beyond uniform drug escalation toward personalized care.

Sriram Sriperumbuduri, Rachel W. Khan, Soyeb Aftab et al. · 0 citations
Review Sep 2026

The PREVENT Equations Evidence Appraisal of Validation and Clinical Implications.

The American Heart Association's PREVENT equations offer a contemporary, race-free alternative to the Pooled Cohort Equations (PCE), incorporating kidney function to estimate 10- and 30-year risks of atherosclerotic cardiovascular disease (ASCVD), heart failure, and total CVD. PREVENT-ASCVD is now recommended for prima...

I. Mortada, Ebrahim Adel Elkolaly, Aaron W. Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.